Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
25
JAGX Quote, Financials, Valuation and Earnings
Last price:
$1.09
Seasonality move
:
107.52%
Day range:
$1.15 - $1.30
52-week range:
$1.00 - $33.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.41x
P/B ratio:
0.48x
Volume:
246.4K
Avg. volume:
298.3K
1-year change:
-94.86%
Market cap:
$1.5M
Revenue:
$11.7M
EPS (TTM):
-$33.98
Analysts' Opinion
-
Consensus RatingJaguar Health, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.50, Jaguar Health, Inc. has an estimated upside of 2042.86% from its current price of $1.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $1.19.
Fair Value
-
According to the consensus of 1 analyst, Jaguar Health, Inc. has 2042.86% upside to fair value with a price target of $25.50 per share.
JAGX vs. S&P 500
-
Over the past 5 trading days, Jaguar Health, Inc. has underperformed the S&P 500 by -2.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Jaguar Health, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Jaguar Health, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Jaguar Health, Inc. reported revenues of $3.1M.
Earnings Growth
-
Jaguar Health, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Jaguar Health, Inc. reported earnings per share of -$6.28.
Enterprise value:
31.1M
EV / Invested capital:
0.86x
Price / LTM sales:
0.41x
EV / EBIT:
--
EV / Revenue:
2.64x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-1.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$7.4M
Return On Assets:
-78.59%
Net Income Margin (TTM):
-348.22%
Return On Equity:
-524.57%
Return On Invested Capital:
-97.4%
Operating Margin:
-234.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $10.7M | $10.5M | $11.8M | $3.1M | $3.1M | |
| Gross Profit | $7.1M | $6M | $7.4M | $2M | $2M | |
| Operating Income | -$33M | -$29.9M | -$32.8M | -$7.3M | -$7.2M | |
| EBITDA | -$30.6M | -$27.5M | -$30.6M | -$6.7M | -$6.7M | |
| Diluted EPS | -$412.92 | -$16.10 | -$33.98 | -$1.05 | -$6.28 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $24M | $25.2M | $22.1M | $36.6M | $29.4M | |
| Total Assets | $59.3M | $51.3M | $45.4M | $58.5M | $49.5M | |
| Current Liabilities | $12M | $26.9M | $12.5M | $19.9M | $36.1M | |
| Total Liabilities | $37.7M | $47.7M | $44M | $42.9M | $45.1M | |
| Total Equity | $21.6M | $3.6M | $1.4M | $15.6M | $4.4M | |
| Total Debt | $25.8M | $32.5M | $35M | $33.9M | $31.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$32.2M | -$29M | -$26M | -$6.3M | -$4.7M | |
| Cash From Investing | $866K | -$10K | -$269K | -- | -$54K | |
| Cash From Financing | $24M | $39M | $16.7M | $3.5M | $6.3M | |
| Free Cash Flow | -$32.6M | -$29M | -$26.3M | -$6.3M | -$4.7M | |
JAGX
Sector
Market Cap
$1.5M
$28.4M
Price % of 52-Week High
3.58%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-460.4%
-1.49%
1-Year Price Total Return
-94.86%
-16.67%
Beta (5-Year)
-0.122
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.24
200-day SMA
Sell
Level
$3.58
Bollinger Bands (100)
Sell
Level
1.44 - 2.18
Chaikin Money Flow
Sell
Level
-3.9M
20-day SMA
Sell
Level
$1.21
Relative Strength Index (RSI14)
Sell
Level
42.79
ADX Line
Sell
Level
17.74
Williams %R
Neutral
Level
-62
50-day SMA
Sell
Level
$1.60
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
2.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.2709)
Sell
CA Score
(Annual)
Level (-4.6921)
Buy
Beneish M-Score
(Annual)
Level (-3.4947)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.9083)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, JAGX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The JAGX average analyst price target in the past 3 months is $25.50.
-
Where Will Jaguar Health, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Jaguar Health, Inc. share price will rise to $25.50 per share over the next 12 months.
-
What Do Analysts Say About Jaguar Health, Inc.?
Analysts are divided on their view about Jaguar Health, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Jaguar Health, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Jaguar Health, Inc.'s Price Target?
The price target for Jaguar Health, Inc. over the next 1-year time period is forecast to be $25.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is JAGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Jaguar Health, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of JAGX?
You can purchase shares of Jaguar Health, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Jaguar Health, Inc. shares.
-
What Is The Jaguar Health, Inc. Share Price Today?
Jaguar Health, Inc. was last trading at $1.09 per share. This represents the most recent stock quote for Jaguar Health, Inc.. Yesterday, Jaguar Health, Inc. closed at $1.19 per share.
-
How To Buy Jaguar Health, Inc. Stock Online?
In order to purchase Jaguar Health, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get JAGX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
JAGX
Sector
P/E ratio
--
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
0.48x
1.81x
Price / LTM sales
0.41x
1.58x
Growth Metrics
JAGX
Sector
Revenue growth
-0.8%
4.62%
Earnings growth
-497.14%
10.7%
Revenue (5-year growth)
15.14%
6.5%
Earnings forecast
-$5.08
-$0.21
Profitability
JAGX
Sector
Profitability FY 2024
$7.4M
$3.6M
Return on invested capital
-97.4%
-31.84%
Return on assets
-78.59%
-27.96%
Return on equity
-524.57%
-37.63%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
13
Balance Sheet
JAGX
Sector
Total cash
$3.5M
$26.4M
Short term investments
--
$25.7M
Total assets
$53.4M
$76.9M
Long term debt
$31.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is down 0.27% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
